Brief: Guard Therapeutics Says Study On RMC-035 Confirms Positive Data

Disruptive Pharma AB (publ)

14/06/2023 10:58

June 14 (Reuters) - Guard Therapeutics International AB
(publ)  GUARD.ST :
    * STUDY RESULTS WITH GUARD THERAPEUTICS’ RMC-035 IN KIDNEY
TRANSPLANTATION CONFIRM PREVIOUSLY POSITIVE DATA ANALYSIS
    * STUDY RESULTS CONFIRM PREVIOUSLY POSITIVE PRELIMINARY DATA
ANALYSIS
    * STUDY RESULTS DEMONSTRATE FAVORABLE PHARMACOKINETIC
PROPERTIES
OF RMC-035 WITHOUT ANY SERIOUS ADVERSE EFFECTS ASSOCIATED WITH
INVESTIGATIONAL DRUG

Source text for Eikon:  ID:nMFN3BHP5l 
Further company coverage:  GUARD.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))